PARG enzymes may have a protective effect against excessive PARP engagement; on the contrary, it is described that the catalytic inhibition of PARG prolongs the levels of ADP-ribosylation on the points of DNA damage induced by chemotherapeutics, triggering cell death in certain cancer models with defects in DNA repair systems, through synthetic lethality [109]. Here, PARP1 is linked to cancer.